Patents by Inventor Marcello Maresca

Marcello Maresca has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230340538
    Abstract: The present disclosure provides proteins, compositions, methods, and kits for improved gene editing efficiency. In some embodiments, the disclosure provides a fusion protein comprising a Cas nuclease and a reverse transcriptase, a DNA polymerase, a DNA ligase, or a combination thereof.
    Type: Application
    Filed: April 7, 2021
    Publication date: October 26, 2023
    Inventor: MARCELLO MARESCA
  • Publication number: 20220162648
    Abstract: The present disclosure provides methods of introducing site-specific mutations in a target cell and methods of determining efficacy of enzymes capable of introducing site-specific mutations. The present disclosure also provides methods of providing a bi-allelic sequence integration, methods of integrating of a sequence of interest into a locus in a genome of a cell, and methods of introducing a stable episomal vector in a cell. The present disclosure further provides methods of generating a human cell that is resistant to diphtheria toxin.
    Type: Application
    Filed: April 9, 2020
    Publication date: May 26, 2022
    Inventors: Marcello MARESCA, Songyuan LI
  • Patent number: 11254928
    Abstract: Provided herein, in some embodiments, are nucleic acid-based tools that may be used for high-throughput functional genomics studies as well as for the generation of knockout (gene inactivation or deletion) or knockin (gene activation or insertion) cell lines. Tools of the present disclosure include an “activatable reporter cassette,” a guide RNA construct and a nuclease that can be used together, for example, to modify and isolate targeted cells of interest.
    Type: Grant
    Filed: January 13, 2017
    Date of Patent: February 22, 2022
    Assignee: ASTRAZENECA AB
    Inventors: Marcello Maresca, Amir Taheri-Ghahfarokhi, Mohammad Bohlooly-Yeganeh, Lorenz M. Mayr
  • Publication number: 20210230630
    Abstract: The present disclosure is directed, in some embodiments, to compositions and methods for inducible modification of a cell genome.
    Type: Application
    Filed: February 3, 2021
    Publication date: July 29, 2021
    Inventors: Marcello MARESCA, Mohammad BOHLOOLY-YEGANEH, Himjyot JAISWAL, Lorenz M. MAYR, Xiufeng XU
  • Publication number: 20210180059
    Abstract: The present disclosure provides a non-naturally occurring CRISPR-Cas system comprising: a Cas9 effector protein capable of generating cohesive ends (stiCas9), and a guide polynucleotide that forms a complex with the stiCas9 and comprising a guide sequence, wherein the guide sequence hybridizes with a target sequence in a eukaryotic cell but does not hybridize to a sequence in a bacterial cell, and wherein the complex does not occur in nature. The present disclosure also provides a method of introducing a sequence of interest into a chromosome of a cell. Finally, the present disclosure provides for a method of modifying one or more nucleotides using seamless mutagenesis.
    Type: Application
    Filed: November 16, 2018
    Publication date: June 17, 2021
    Inventors: MARCELLO MARESCA, AMIR TAHERI-GHAHFAROKHI, FREDERIK KARLSSON, MOHAMMAD BOHLOOLY-YEGANEH, LORENZ MARTIN MAYR
  • Patent number: 10947559
    Abstract: The present disclosure is directed, in some embodiments, to compositions and methods for inducible modification of a cell genome.
    Type: Grant
    Filed: October 14, 2016
    Date of Patent: March 16, 2021
    Assignee: ASTRAZENECA AB
    Inventors: Marcello Maresca, Mohammad Bohlooly-Yeganeh, Himjyot Jaiswal, Lorenz M. Mayr, Xiufeng Xu
  • Publication number: 20190024074
    Abstract: Provided herein, in some embodiments, are nucleic acid-based tools that may be used for high-throughput functional genomics studies as well as for the generation of knockout (gene inactivation or deletion) or knockin (gene activation or insertion) cell lines. Tools of the present disclosure include an “activatable reporter cassette,” a guide RNA construct and a nuclease that can be used together, for example, to modify and isolate targeted cells of interest.
    Type: Application
    Filed: January 13, 2017
    Publication date: January 24, 2019
    Inventors: Marcello MARESCA, Amir TAHERI-GHAHFAROKHI, Mohammad BOHLOOLY-YEGANEH, Lorenz M. MAYR
  • Publication number: 20180305714
    Abstract: The present disclosure is directed, in some embodiments, to compositions and methods for inducible modification of a cell genome.
    Type: Application
    Filed: October 14, 2016
    Publication date: October 25, 2018
    Inventors: Marcello MARESCA, Mohammad BOHLOOLY-YEGANEH, Himjyot JAISWAL, Lorenz M. MAYR, Xiufeng XU
  • Patent number: 9567608
    Abstract: The present invention relates to genetic techniques employing the direct ligatation of an external DNA fragment generated in situ by the same ZFNs that target the genome. ObLiGaRe, i.e., the obligated ligation-gated recombination, is a new method for genetic engineering using custom designed nucleases, and a strategy of site-specific gene insertion utilizing the NHEJ pathway. It applies a similar logic to the one used in unidirectional loxP sites (Oberdoerffer et al., 2003) but maintains all the advantages and flexibility of CDNs.
    Type: Grant
    Filed: February 26, 2015
    Date of Patent: February 14, 2017
    Assignee: Novartis AG
    Inventors: Yi Yang, Marcello Maresca
  • Publication number: 20160032321
    Abstract: The present invention relates to genetic techniques employing the direct ligatation of an external DNA fragment generated in situ by the same ZFNs that target the genome. ObLiGaRe, i.e., the obligated ligation-gated recombination, is a new method for genetic engineering using custom designed nucleases, and a strategy of site-specific gene insertion utilizing the NHEJ pathway. It applies a similar logic to the one used in unidirectional loxP sites(Oberdoerffer et al., 2003) but maintains all the advantages and flexibility of CDNs.
    Type: Application
    Filed: February 26, 2015
    Publication date: February 4, 2016
    Applicant: NOVARTIS AG
    Inventors: Yi YANG, Marcello MARESCA
  • Patent number: 8728820
    Abstract: The invention provides a method for inserting a single stranded replacement nucleic acid into a target nucleic acid, the method comprising the steps of: a) generating a single stranded replacement nucleic acid from a double stranded nucleic acid, wherein the double stranded nucleic acid is adapted at one or both of its 5? ends such that preferential degradation of one strand and/or strand separation generates the single stranded replacement nucleic acid, wherein the single stranded replacement nucleic acid comprises a 5? region that is identical to sequence on the target nucleic acid, a 3? region that is identical to sequence on the target nucleic acid and optionally a replacement region between the 5? and 3? regions that is not identical to sequence on the target nucleic acid, b) exposing the target nucleic acid to the single stranded replacement nucleic acid under conditions suitable for recombination to occur between the single stranded replacement nucleic acid and the target nucleic acid, and c) selecting
    Type: Grant
    Filed: February 20, 2009
    Date of Patent: May 20, 2014
    Assignee: Gene Bridges GmbH
    Inventors: Marcello Maresca, Axel Steffen Erler, Jun Fu, Philipp Martin Seibert, Adrian Francis Stewart, Youming Zhang
  • Publication number: 20110165630
    Abstract: The invention provides a method for inserting a single stranded replacement nucleic acid into a target nucleic acid, said method comprising the steps of: a) generating a single stranded replacement nucleic acid from a double stranded nucleic acid, wherein the double stranded nucleic acid is adapted at one or both of its 5? ends such that preferential degradation of one strand and/or strand separation generates the single stranded replacement nucleic acid, wherein the single stranded replacement nucleic acid comprises a 5? region that is identical to sequence on the target nucleic acid, a 3? region that is identical to sequence on the target nucleic acid and optionally a replacement region between the 5? and 3? regions that is not identical to sequence on the target N nucleic acid, b) exposing the target nucleic acid to the single stranded replacement nucleic acid under conditions suitable for recombination to occur between the single stranded replacement nucleic acid and the target nucleic acid, and c) select
    Type: Application
    Filed: February 20, 2009
    Publication date: July 7, 2011
    Applicant: Gene Bridges GmbH
    Inventors: Marcello Maresca, Axel Steffen Erler, Jun Fu, Philipp Martin Seibert, Adrian Francis Stewart, Youming Ahang